We investigated the antitumor effects of FR901228, a HDAC inhibitor, on human osteosarcoma cells, in vitro and in vivo to explore its possible utility in the treatment of pediatric bone cancers. FR901228 caused marked growth inhibition with a 50% inhibitory concentration of 1.2-7.3 nM and induction of apoptosis in all eight osteosarcoma cell lines tested. These effects of FR901228 were also observed in vivo xenograft models on BALB/c nude mice, and treatment with 5.6 mg/kg/day resulting in a >70% reduction in the mean final tumor volume compared with the mean initial tumor volume. TUNEL assays demonstrated extensive apoptosis in tumor sections of mice treated with FR901228. Induction of apoptosis was preceded by increased expression of Fas ligand (FasL) mRNA, resulting in expression of membrane-bound FasL, which was followed by sequential activation of caspase-8 and -3. The level of apoptosis induction was reduced using a neutralizing anti-FasL antibody and overexpression of either the dominantnegative FADD or the viral FLICE inhibitory protein.
We investigated the antitumor effects of FR901228, a HDAC inhibitor, on human osteosarcoma cells, in vitro and in vivo to explore its possible utility in the treatment of pediatric bone cancers. FR901228 caused marked growth inhibition with a 50% inhibitory concentration of 1.2-7.3 nM and induction of apoptosis in all eight osteosarcoma cell lines tested. These effects of FR901228 were also observed in vivo xenograft models on BALB/c nude mice, and treatment with 5.6 mg/kg/day resulting in a >70% reduction in the mean final tumor volume compared with the mean initial tumor volume. TUNEL assays demonstrated extensive apoptosis in tumor sections of mice treated with FR901228. Induction of apoptosis was preceded by increased expression of Fas ligand (FasL) mRNA, resulting in expression of membrane-bound FasL, which was followed by sequential activation of caspase-8 and -3. The level of apoptosis induction was reduced using a neutralizing anti-FasL antibody and overexpression of either the dominantnegative FADD or the viral FLICE inhibitory protein.
Furthermore, treatment with a suboptimal dose ofIntroduction
Osteosarcoma is the most common primary malignant bone tumor occurring mainly in children and young adolescents (Himelstein, 1998) . Owing to frequent systemic metastases, adjuvant chemotherapeutic treatment is mandatory to achieve a disease-free state in addition to appropriate surgical treatments (Bramwell, 2000) . Applications of multidrug intensive chemotherapy have substantially improved the prognosis for patients with no detectable metastases at diagnosis, and the long-term survival rate of nearly 70% is noted at specialized sarcoma centers (Rosen et al., 1979; Eilber et al., 1987; Link et al., 1991; Bramwell et al., 1992; Meyers et al., 1992) . A considerable portion of similar patients has a poor response to any kind of chemotherapeutic protocols. In patients with detectable metastases at diagnosis (approximately 10-20% of all cases) or with unresectable pelvic or axial skeleton tumors, the prognosis remains poor with 3-year survival rates ranging between 11 and 56% (Beron et al., 1985; Marina et al., 1992; Ozaki et al., 2003) . Precise molecular mechanisms underlying the drug-resistance have remained to be investigated. Mutations of two tumor suppressor genes, the p53 and retinoblastoma (Rb) genes are molecular hallmarks of osteosarcomas (Toguchida et al., 1992; Wadayama et al., 1994) , and several studies have shown the relationship of these genes with drug resistance, some of which were related to the induction of apoptosis, but definite conclusions have not been reached (Hickman et al., 2002) . The development of new antitumor agents or chemicals that can enhance the effects of current chemotherapeutic drugs will be expected to improve the prognosis. Among new antitumor therapeutic approaches, one of the most promising is the application of histone deacetylase (HDAC) inhibitor. Histone acetylation plays a key role in regulating transcription by modulating chromatin structure, and is regulated by the activity of histone acetyltransferase and HDAC (Grunstein, 1997; Struhl, 1998) . In general, histone acetylation is associated with activation of transcription, whereas histone deacetylation is associated with repression of transcription. Several compounds function as HDAC inhibitors even at a low potency, the result being an accumulation of acetylated histones and an increase in transcriptionally active chromatin (Yoshida et al., 1990; Nakano et al., 1997; Archer et al., 1998; Cuisset et al., 1998; Finnin et al., 1999) . Some classes of HDAC inhibitors are under clinical development and these have anticancer effects on a variety of cancer cells. These classes are the short-chain fatty acids, phenylbutyrate (Gore and Carducci, 2000) and valproic acid (Phiel et al., 2001) , the benzamides, CI-994 (Prakash et al., 2001 ) and MS-27-275 (Jaboin et al., 2002) , and the hydroxamic acids, suberoylanilide hydroxamic acid (Richon et al., 1998) .
FR901228, a natural cyclic depsipeptide with an activity as HDAC inhibitor (Ueda et al., 1994b; Nakajima et al., 1998) , is an antitumor agent which functions in cell cycle arrest, differentiation, and/or apoptosis and suppresses growth of transplanted tumors in mice (Ueda et al., 1994a; Sandor et al., 2000; Kosugi et al., 2001; Weiser et al., 2001; Sasakawa et al., 2002) . To evaluate the clinical safety and efficacy of FR901228, clinical trials with non-small cell lung cancer and cutaneous T-cell lymphoma are ongoing in the United States (Piekarz et al., 2001; Sandor et al., 2002) . We now report that FR901228 effectively induces apoptosis in human osteosarcoma cells, both in vitro and in vivo, irrespective of the status of p53 and Rb genes, and FR901228-induced apoptosis occurs through the combination of Fas ligand (FasL) upregulation and sensitization to Fas signaling in tumor cells.
Results

FR901228 inhibits proliferation and induces apoptosis in human osteosarcoma cells in vitro
We first examined the effect of FR901228 on proliferation of eight human osteosarcoma cell lines using WST-1 assays. The genetic status of p53 and Rb genes in each cell line was analysed in our laboratory using previously described methods (Toguchida et al., 1992; Wadayama et al., 1994 and precise data not shown) (Table 1) . Cells were cultured with FR901228 at various concentrations for 72 h. As shown in Figure 1 , FR901228 induced a marked growth inhibition in a dose-dependent manner against all eight cell lines tested, and the 50% inhibitory concentration (IC 50 ) value ranging from 1.2 nM (HOS) to 7.3 nM (Takao) ( Table 1 ). There was no consistent association of specific genotype of p53 and/or Rb genes with the value of IC 50 . Growth inhibition seen with the use of FR901228 was associated with the appearance of floating, rounded, and shrinking cells in culture medium (data not shown). To investigate whether these were caused by necrosis or apoptosis, drug-treated cells of each cell line was examined using flow cytometry after staining the cells with propidium iodide. As shown in Figure 2a , apoptosis was induced in all eight cell lines used in a time-dependent manner, and the fraction of apoptotic cells was 16-34, 35-81, and 63-93% at 24, 48 , and 72 h after the treatment, respectively. Representative profiles of sub-G1 population of OST and Takao cells are shown in Figure 2b . Induction of apoptosis was further demonstrated by chromatin condensation and nuclear fragmentation noted with the use of Hoechst 33342 staining (Figure 2c ). These results indicate that FR901228 in a nanomolar dose range induced apoptosis in human osteosarcoma cells in vitro.
FR901228 increases acetylation of histone H3 and H4 in human osteosarcoma cells
To examine the relationship between the FR901228-induced apoptosis and histone acetylation, nuclear pellets were prepared from OST cells after treatment with 10 nM of FR901228, and the amount of acetylated histones was determined using antiacetylated histone H3 or H4 antibodies (Figure 3a) . Increase of acetylated histone H3 and H4 was observed as early as 1 h after FR901228 treatment, and showed further accumulation in a time-dependent manner. Rapid induction of acetylation was further confirmed by immunofluorescence staining (Figure 3b ). OST cells Figure 3a . This increase of acetylated histone H3 and H4 was observed in all the eight osteosarcoma cell lines (data not shown).
FR901228 upregulates FasL expression and activates caspase-8 and -3
The following in vitro experiments were performed in four cell lines, which showed the different genetic status of p53 and Rb gene; OST (p53/Rb, wt/wt), OS690 (wt/ mt), HOS (mt/wt), and Takao (mt/mt) (Table 1) . First, as all eight human osteosarcoma cell lines tested in this study, constitutively express Fas (Hamada et al., 1999; Kinoshita et al., 2000; Lafleur et al., 2001) , including Takao and OS690 cells (data not shown), we investigated expression of FasL and Fas for apoptosis-related genes upregulated by FR901228. As for FasL, there was no detectable FasL mRNA expression observed in OST cells, while treatment with 10 nM FR901228 induced expression of FasL gene as early as 2 h after treatment by reverse transcriptase-polymerase chain reaction (RT-PCR) ( Figure 4a ). In accordance with mRNA data, membrane-bound FasL was upregulated as early as 3 h after treatment with FR901228, prior to apoptosis in OST cells while untreated cells showed undetectable levels of FasL ( Figure 4b ). The same results were obtained in other three cell lines (data not shown). To determine whether FR901228 also modulated Fas expression in human osteosarcoma cell lines, we analysed the expression of cell surface Fas using flow cytometry. We observed a slight decrease in Fas-specific staining intensity after 4 h of treatment in all four cell lines up to 24 h (data not shown).
To investigate the effect of upregulated FasL expression, downstream molecules were analysed. Treatment of the four osteosarcoma cell lines with FR901228 for 24 h led to a reduction of procaspase-8 with accumulation of the cleavage product of procaspase-8 ( Figure 5a ). Similar results were observed for caspase-3, in which the latent form (p32) was cleaved into the catalytically active effector protease (p17) (Figure 5a ). Caspase-3 protease activation was accompanied by cleavage of Poly(ADP-ribose) polymerase (PARP) (116 kDa) into an 85 kDa fragment ( Figure 5a ). Time-course analyses using OST cells showed that caspase-8 cleavage was detectable at 6 h, followed by cleavage of the effector caspase-3 and PARP at 12 h ( Figure 5b ). Similar results were obtained in other three cell lines (data not shown). To confirm the involvement of caspase-3 and-8 in the FR901228-induced apoptosis, we did the sub-G 1 assays in the presence of 200 mM Z-DEVD-FMK (inhibitor of caspase-3) or Z-IETD-FMK (inhibitor of caspase-8). As shown in Figure 6 , each of the tested inhibitors markedly reduced the FR901228-induced apoptosis in OST cells. Similar results were obtained in other three cell lines (data not shown).
Requirement of Fas/FasL system for FR901228-induced apoptosis
To confirm that the FR901228-induced apoptosis was through the Fas/FasL signaling pathway, blocking experiments were done. First, to block the FasL-Fas interaction, OST cells were preincubated with anti-FasL antibody (200 ng/ml) before the treatment with FR901228, and the fraction of apoptotic cells was reduced by 61% ( Figure 7a ; P ¼ 0.007, respectively). Intracellular signaling from Fas to downstream molecules was blocked by transient expression of either 
FR901228 sensitizes to agonistic anti-Fas antibody-mediated apoptosis
We then attempted to determine whether the FR901228 could modulate the cell death pathway triggered by the cell-death receptor Fas of human osteosarcoma cells. At the indicated time after treatment with 10 nM FR901228, cleavage of caspase-8 and -3, and PARP in OST cells were examined using Western blot analysis. The bands just below the procaspase-8 (55/50 kDa) and the procaspase-3 (32 kDa) were nonspecific bands
Regulation of Fas/Fas ligand system by FR901228 T Imai et al
For this purpose, OST, OS690, HOS, and Takao cells were exposed to the agonistic anti-Fas antibody (CH-11), with or without a suboptimal concentration of FR901228 for 24 h, then apoptosis was assessed using flow cytometry. As shown in Figure 8 , treatment with either 2 nM FR901228 or 500 ng/ml CH-11 led to only low levels of apoptosis (o5%), whereas treatment with both FR901228 and CH-11 led to 7.3-, 10.3-, 12.5-and 7.9-fold increases in apoptosis when compared to findings in cells treated with FR901228. These results suggested that FR901228 sensitizes to Fas-mediated apoptosis or synergistically acts with agonistic anti-Fas antibody in the process of apoptosis induction in human osteosarcoma cell lines.
FR901228 inhibits tumor growth in human osteosarcomas in vivo
We then examined the antitumor activity of FR901228 against growth of osteosarcoma cells in vivo using OST and Takao cells. These two cell lines were selected because they produced in vivo tumors more consistently than other cell lines in the preliminary experiments. Administration of FR901228 3 times at 4-day intervals led to a significant suppression of growth in all established tumors tested. Doses of 0.7, 1.4, 2.8, and 5.6 mg/kg/day caused a dose-dependent mean tumor size reduction of 53, 55, 75, and 91% for OST-derived tumor and 55, 79, 90, and 98% for Takao-derived tumor, respectively, compared to the mean final tumor volume of vehicle-treated control animals ( Figure 9 ). Mice injected with OST cells exhibited regression of tumor burden upon treatment with 2.8 mg/kg (-28%) and 5.6 mg/kg (-74%) of the HDAC inhibitor. Mice injected with Takao cells also exhibited regression of tumor burden upon treatment with 5.6 mg/kg (-88%) of FR901228 and these decreases were significant (P ¼ 0.001). The toxicity of FR901228 was assessed by monitoring body weight and survival of mice in each group at the conclusion of the 15 day study. There were no major toxicities observed in the drug-treated groups.
Histological examination showed extensive apoptotic changes in tumor tissue. At 15 days after the initial These results suggested that FR901228 effectively killed tumor cells through induction of apoptosis in vivo.
Discussion
Remodeling the chromatin structure has been extensively studied in the broad field of cell biology, and applications of remodeling modifiers, such as HDAC inhibitor, to manipulate gene expression have opened a new direction for cancer therapy (Marks et al., 2001a; Richon and O'Brien, 2002) . Mechanisms of growth inhibition by HDAC inhibitor, are not fully understood, and may differ in each combination of reagent and tumor cells. As osteosarcoma cells exhibit extensive apoptosis both in vitro and in vivo, we focused on mechanisms of apoptosis induction by FR901228. The Fas (Apo-1/CD95)/FasL system is one of the key regulators of apoptosis in mammalian cells and many chemotherapeutic agents use this system to induce apoptosis (Debatin, 1999; Nicholson, 2000) . Cross-linking of Fas by either its natural ligand, FasL, or agonistic antibodies can induce apoptosis in Fas-expressing cells (Trauth et al., 1989; Yonehara et al., 1989; Suda et al., 1993; Nagata and Golstein, 1995) . We have found that FR901228 inhibited the growth of human osteosarcoma cell lines by inducing apoptosis through activation of the Fas/FasL pathway in vitro. Sequential activation of caspase-8 and -3 and blocking experiments with anti-FasL neutralizing antibody or overexpression of viral FLIP E8 or FADD-DN, indicate that the Fas signaling pathway is responsible for FR901228-induced apoptosis. This activation of the Fas/FasL system by FR901228 has at least two distinct mechanisms. First, FR901228 upregulated the mRNA expression of FasL, leading to the cell surface expression of FasL protein. As the induction of FasL mRNA expression was observed as early as 2 h after the administration of FR901228, it is likely that FasL is Figure 8 Sensitization to Fas-mediated apoptosis by FR901228. OST, OS690, HOS, or Takao cells were cultured with 500 ng/ml agonistic anti-Fas antibody (CH-11) for 24 h in the presence or absence of 2 nM FR901228, and sub-G1 was determined using flow cytometry. Isotype control IgM-treatment with FR901228 showed no difference with FR901228 alone (data not shown). Data are the mean7s.d. of three individual experiments 
Regulation of Fas/Fas ligand system by FR901228 T Imai et al
the direct target for FR901228-mediated histone acetylation. Similar mechanisms by HDAC inhibitors have been proposed. Expression of FasL was induced by FR901228 in primary and metastatic human uveal melanoma cell lines (Klisovic et al., 2003) , by Mcarboxycinnamic acid bishydroxamide (CBHA) in human neuroblastoma cell lines (Glick et al., 1999) , and by apicidin in an acute promyelocytic leukemia cell line (Kwon et al., 2002) , although the expression of Fas was also upregulated in these reports. Interestingly, it has been observed that FR901228 inhibits the expression of FasL through the downregulation of c-myc in 3T3 fibroblasts (Wang R et al., 1998) . We examined the effects of FR901228 on the expression of c-myc in human osteosarcoma cell lines (OST, Takao, MG63, and OS690) by Western blotting with anti-c-myc antibody up to 24 h. We have found that FR901228 showed no effects on the expression level of c-myc in all four osteosarcoma cell lines tested (data not shown). In the other recent report, FR901228 caused apoptosis in lymphocytic leukemia cells by activation of caspase 8 through the TNF-receptor pathway, while the level of Fas remained unaltered (Aron et al., 2003) . These data suggested the presence of tissue and cell-type-specific effects of HDAC inhibitors.
All the four human osteosarcoma cell lines we tested were resistant to apoptosis by Fas stimulation alone despite the constitutively expressed cell surface Fas (Fellenberg et al., 1997; Hamada et al., 1999; Kinoshita et al., 2000; Lafleur et al., 2001) . We speculated that FR901228 not only induces FasL expression, but modulates mechanisms by which osteosarcoma cells might inactivate Fas signaling. As we expected, FR901228 dramatically sensitized human osteosarcoma cells to Fas-mediated apoptosis and synergistically acted with agonistic anti-Fas antibody. Sensitization to Fasmediated apoptosis by HDAC inhibitor-butyrate has been reported in an acute lymphoblastic leukemia cell line and colon cancer cell lines but the underlying mechanisms were not elucidated (Bonnotte et al., 1998; Kinoshita et al., 2000; Bernhard et al., 2001 ). We investigated several proteins known to participate in the Fas-apoptosis cascade (Medema et al., 1997; Nagata, 1997) . As protein levels of Fas, FADD, caspase-8, and FLIP S þ L were not affected, these proteins are probably not direct targets of FR901228-induced histone acetylation in our system (data not shown). To our knowledge, this is the first report that HDAC inhibitor induced functional FasL expression followed by Fas/FasLdependent apoptosis and sensitized to Fas-mediated apoptosis in cancer cells in the same system. The potential for FR901228 to sensitize cells to the Fas signal is of great importance in clinical use.
Recent evidence suggests that cytotoxic drugs conventionally used for treatment of osteosarcoma (such as cisplatin, doxorubicin, etoposide, or methotrexate) kill tumors through induction or upregulation of FasL expression on the tumor cell surface (Fulda et al., 1998a, b; Kaufmann and Earnshaw, 2000; Herr and Debatin, 2001 ) and sensitize tumors to Fas-mediated apoptosis (Mizutani et al., 1997; Kinoshita et al., 2000; Wu et al., 2000) . Cisplatin induces apoptosis in osteosarcoma cells through sequential activation of caspase-8, -3, and -6 (Seki et al., 2000) . The level of induction, however, was influenced by the status of the p53 gene, as cells with a mutant p53 gene are resistant to the induction of apoptosis (Wang LH et al., 1998) . On the other hand, Fas signaling was shown to be sensitized by cisplatin in osteosarcoma cells (Kinoshita et al., 2000) As FR901228 induced apoptosis in all osteosarcoma cell lines examined in this study, irrespective of the p53 gene status, simultaneous administration of cisplatin and FR901228 may overcome the effects of host factors such as the presence of mutant p53 gene. In addition, FR901228 may become a candidate for clinical use as a therapeutic agent for osteosarcoma in combination with agonistic anti-Fas monoclonal antibody. Recently, we prepared a novel humanized agonistic anti-Fas monoclonal antibody HFE7A which has no hepatotoxicity (Haruyama et al., 2002; Yonehara, 2002) . As blockage of the Fas/FasL system failed to completely inhibit FR901228-induced apoptosis, it is also likely that other apoptotic pathways are involved in inducing apoptosis with this agent. There are two known major apoptotic pathways; the death receptor pathway and the mitochondrial pathway. We previously reported that agonistic anti-Fas antibody induces mitochondrial dysfunction in the early process of apoptosis in Jurkat cells (Adachi et al., 1997) . The mitochondrial pathway is less likely to be involved in our system because we were unable to observe the loss of mitochondrial membrane potential, activation of caspase-9, release of cytochrome c into the cytosol, translocation of Bax into the mitochondria, and cleavage of Bid for up to 24 h after FR901228-treatment (data not shown).
In this study, we have demonstrated the evidence indicating the FasL gene as one of hyperacetylated gene after the treatment with FR90128. The effects for other genes, however, remain to be investigated. Recent study has found correlations between increased acetylation of histones H3 and H4 and induction of osteocalcin gene during osteoblast differentiation . Apoptosis is a fundamental process of osteoblast differentiation and upregulation of Bcl-2, p53, c-fos, and Msx-2 occurs during bone remodeling and osteoblast maturation (Lynch et al., 1998) . In reviewing factors regulating apoptosis and bone turnover, roles of cytokines, growth factors, members of tumor necrosis factor pathway and the extracellular matrix have been discussed (Hock et al., 2001 ). Thus, FR901228 may activate an apoptotic pathway in osteosarcoma cells that is normally linked to progression of bone cell differentiation. Further investigation of the effects of FR901228 on other apoptotic pathways is needed.
In summary, our data suggest a potential clinical use of FR901228 particularly for patients with osteosarcoma, alone, in combination with conventional agents or with agonistic anti-Fas monoclonal antibody.
Materials and methods
Cell lines
We used eight human osteosarcoma cell lines. G292, HOS, and MG63, were purchased from the Institute for Fermentation (Osaka, Japan), Saos2 and U2OS were from American Type Culture Collection (Manassas, VA, USA), and OST was from RIKEN Cell Bank (Tsukuba, Japan). The human osteosarcoma cell line Takao is a clonal cell line from the parental cell line, SU (Ishii et al., 1982) , which was kindly provided by Dr S Ishi, from Sapporo Medical University. OS690 was established in our laboratory from a biopsy sample of a patient, who had multiple lung metastases at the initial presentation. All cell lines were maintained in DMEM supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin at 371C in 5% CO 2 .
Reagents and antibodies
FR901228 was kindly provided by Fujisawa Pharmaceutical Co., Ltd. (Tokyo, Japan). Neutralizing anti-FasL antibody 4H9 (Gastman et al., 1999) , agonistic anti-Fas antibody CH-11, and isotype-matched control IgG and IgM were from MBL (Nagoya, Japan). Mouse anti-caspase-8 antibody, rabbit anticaspase-3 antibody, and anti-PARP antibody, were purchased from BD PharMingen (San Diego, CA, USA). Mouse anti-bactin antibody was from Sigma (St Louis, MO, USA). Secondary antibodies conjugated to horseradish peroxidase were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Z-DEVD-FMK and Z-IETD-FMK were purchased from Kamiya Biomedical Company (Seattle, WA, USA).
Cell viability assays
The cytotoxic effects of FR901228 were determined in WST-1 assays (Dojindo, Kumamoto, Japan). Cells were plated into 96-well flat-bottomed plates in triplicate wells (2 Â 10 4 cells/ well) and incubated overnight at 371C, then cells were incubated with FR901228 in various concentrations. After 72 h of treatment, WST-1 was added to each well, followed by incubation for 4 h at 371C. Absorbance at 450 nm against a reference wavelength of 650 nm was measured using a micro titer plate reader (Bio-Rad Laboratories, Hercules, CA, USA). Results were expressed as a percentage of the absorbance of control (untreated) cells.
Apoptosis assays
Adherent and nonadherent cells were harvested, washed once with PBS, and fixed in 70% ethanol for at least 1 h. After washing with PBS, cells were resuspended in propidium iodide solution (50 mg/ml propidium iodide and 0.5 mg/ml RNase in PBS (pH 7.4)) for 30 min in the dark. DNA contents were analysed using FACSCalibur and CELL Quest Software (Becton Dickinson, San Jose, CA, USA). The data from 10 000 cells were collected and analysed. Sub-diploid (sub-G 1 ) populations were calculated as an estimate of the apoptotic cell population.
Cell morphology
After treatment with FR901228 for 24 h, cells were collected after being washed once with ice-cold PBS. Cells were attached to the slide by cytospin (800 r.p.m., 2 min), air-dried, fixed, and stained with Hoechst 33342 (Molecular Probes Inc., Eugene, OR, USA). The stained cells were examined using fluorescence microscopy.
Histone acetylation
Nuclei were placed in lysis buffer containing 10 mM Tris-HCl (pH 6.5), sodium bisulfite, 1% Triton X-100, 10 mM MgCl 2 , 8.6% sucrose, and extracted by Dounce homogenization. Histones were acid-extracted from the nuclear pellets. Acetylation of core histones in the cells was determined by immunoblotting using rabbit polyclonal antibodies against hyperacetylated histone H3 and histone H4 (Upstate Biotechnology, Lake Placid, NY, USA). As a control for the amount of protein loading, parallel gels were stained with Coomassie brilliant blue. Immunofluorescence staining was performed on fixed cells grown on glass coverslips. Briefly, the cells were fixed in 95% ethanol/5% acetic acid and blocked in 8% BSA in PBS. After overnight incubation with antibodies against hyperacetylated histone H3, cells were stained with goat antirabbit Cy3-conjugated secondary antibody (Vector Laboratories, Burlingame, CA, USA). Slides were visualized under a fluorescence microscope.
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RT-PCR analysis for FasL mRNA
For RT-PCR analysis, RNA was isolated from cells using the TRizol reagent (Life Technologies Inc., Rockville, MD, USA). cDNAs were synthesized from 1 mg of total RNA using oligodT primers with Superscript II First-Strand Synthesis System for RT-PCR (Life Technologies Inc.). A pair of intronspanning primers specific for human FasL cDNA (5 0 primer, 5 0 -GGATTGGGCCTGGGGATGTTTCA-3 0 ; 3 0 primer, 5 0 -TTGTGGCTCAGGGGCAGGTTGTTG-3 0 ) was used to amplify the 344 bp product, as described (O'Connell et al., 1996) . A specific primer pair (5 0 primer, 5 0 -GTGGGGCG CCCCAGGCACCA-3 0 ; and 3 0 primer, 5 0 -CTCCTTAATGT-CACGCACGATTTC-3 0 ) was used to amplify the 540 bp product from the cDNA of b-actin gene. After cDNA synthesis, PCR amplification of FasL was performed with 25 cycles of 941C for 30 s, 631C for 30 s, and 721C for 30 s. For bactin, PCR amplification was performed with 25 cycles. PCR products were analysed on a 2% agarose gel.
Flow cytometric analysis of FasL membrane expression
The cell surface expression of the FasL was assessed by flow cytometric analysis. Cells were treated with 10 nM FR901228 for 0, 1, 2, 3, 6, and 12 h, and 1 Â 10 6 cells were incubated with 1 mg of biotin conjugated mouse anti-FasL antibody (BD PharMingen) or biotinylated isotype-matched control antibody (BD PharMingen) for 30 min on ice. After washing in PBS, the cells were incubated with phycoerythrin-conjugated streptavidin (eBioscience, PI, Switzerland) for 30 min on ice. After being washed twice in PBS, the cells were analysed using flow cytometry.
Western blotting
Both floating and adherent cells were collected and total cell lysates were prepared using lysis buffer (10 mM Tris (pH 7.5), 130 mM NaCl, 1% Triton X-100, 10 mM NaF, 10 mM NaPi, 10 mM NaPPi, and protease inhibitors (protease inhibitor cocktail; BD PharMingen)). Protein concentration was measured using the methods of Bradford with bovine serum albumin as the standard (Bradford, 1976) . Equal amounts (20-40 mg) of whole cell lysates were loaded into a 7.5-15% SDSpolyacrylamide gel and transferred to PVDF membrane (Millipore, Billerica, MA, USA). The membrane was rinsed in TBS-T solution (0.1% Tween 20 in TBS, pH 7.5) and incubated in blocking buffer (5% skim milk in TBS-T) at room temperature. The blocked membranes were then incubated with specific primary antibody at 41C overnight and washed with TBS-T three times every 15 min, followed by incubation with a secondary antibody at room temperature for 1 h. After washing in TBS-T, the immunoreactive bands were visualized using enhanced chemiluminescence kits (Amersham Pharmacia Biotec, Buckinghamshire, UK).
Transient transfection
OST cells were transiently transfected with pME18S-FLAGtagged FADD-DN (containing only the death domain), pME18S-FLAG-tagged viral FLIP E8 (equine herpes virus 2 protein E8), or pME18S empty vector (Imai et al., 1999; OhYama et al., 2000) together with an EGFP-expression vector using the SuperFect Transfection Reagent (QIAGEN GmbH, Hilden, Germany). At 48 h after transfection, FR901228 was added to the cells then incubated for 24 h. Sub-G 1 DNA content of the GFP-positive population was measured for assessment of apoptosis among cells transiently cotransfected with an EGFP-encoding vector. Cells were harvested after treatment, fixed in 4% paraformaldehyde and permeabilized with 70% ethanol, then resuspended in propidium iodide solution. DNA contents in 10 000 GFP-positive cells were analysed using flow cytometry. Transfection efficiency, as determined using an EGFP vector, was reproducible at over 50% (55-70%).
In vivo antitumor activity of FR901228
The antitumor activity of FR901228 against human osteosarcomas was evaluated after a s.c. injection into male BALB/c nude mice, 5 weeks of age (CLEA Japan Inc., Tokyo, Japan). Tumor cells (1 Â 10 7 of OST or Takao) were suspended in 200 ml PBS and injected s.c. into the back of the mice. Growth of OST or Takao-derived tumors became evident after 5 or 14 days, and then the mice were grouped into five of six each (day 0). For administration, FR901228 was dissolved and diluted in a vehicle of PBS containing 10% polyoxyethylated hydrogenated castor oil (NOF Corporation, Tokyo, Japan) and the diluents served as the vehicle. Drug doses and scheduling were based on the maximally tolerated dose from murine studies on human solid tumors (lung carcinomas and lung, stomach, and mammary adenocarcinomas) (Ueda et al., 1994a) . Each group of mice received 0.7, 1.4, 2.8, or 5.6 mg/kg FR901228 by i.v. through a lateral tail vein on days 0, 4, and 8. Control groups of mice were injected with vehicle only. Mice were followed every 3-4 days by measuring the size of the s.c. tumors. In brief, calipers were used to determine the maximal (a) and minimal (b) diameters, and tumor volume was then calculated as volume ¼ a Â b 2 Â p/6, as described (Murakami et al., 2002) . Treatment-related toxicity was based on serial weight measurements.
After 15 days, the mice were killed, and the effects of FR901228 on tumor tissues were investigated after H&E staining and TUNEL assays, using Apoptosis in situ Detection Kit (peroxidase; Wako Pure Chemical Industries Ltd., Osaka, Japan). All animal experiments were done in accordance with Institutional Guidelines for Animal Experiments of Kyoto University.
Statistical analysis
Differences among means in vitro were analysed using twosided Student's t-test. Differences among the results for experiments of tumor growth in vivo were assessed using the two-sided Kruskal-Wallis H-test followed by Bonferroni's multiple comparison tests. A P-value o0.05 was considered significant.
